Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...
Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist ... dose given as a weekly injection, meeting its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback